succinic acid bis-(3,5-dibromo-2-hydroxy-benzyl ester) | 87458-18-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: succinic acid bis-(3,5-dibromo-2-hydroxy-benzyl ester)
• 英文别名: Bernsteinsaeure-bis-(3,5-dibrom-2-hydroxy-benzylester)；Bis-(3.5-dibrom-2-hydroxy-benzyl)-succinat；Butanedioic acid,1,4-bis(4,6-dibromo-2-carboxyphenyl) ester；bis[(3,5-dibromo-2-hydroxyphenyl)methyl] butanedioate
• CAS: 87458-18-2
• 化学式: C₁₈H₁₄Br₄O₆
• 分子量: 645.922
• InChiKey: QQMBEZQCWPZYIY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  93.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2,4-二溴-6-溴甲基苯酚 、 alkaline earth salt of/the/ methylsulfuric acid 在 苯 作用下， 生成 succinic acid bis-(3,5-dibromo-2-hydroxy-benzyl ester)
  参考文献：
  名称：

  Some Derivatives of Dibromohydroxybenzyl Bromide

  摘要：

  DOI：

  10.1021/ja01337a066

文献信息

• Hemoglobin Derivative Co-conjugated with Fatty Acid-linked PEG and Alkoxy PEG as a Blood Substitute
  申请人：SunBio, Inc.

  公开号：US20210401949A1

  公开（公告）日：2021-12-30

  The invention relates to hemoglobin derivative, particularly hemoglobin which is co-conjugated with both fatty acid-linked polyethylene glycol (FA-PEG) derivatives and alkoxy polyethylene glycol (alkoxy-PEG) derivatives, and a method for making such hemoglobin derivative. Various embodiments of the invention include crosslinked hemoglobin which is co-conjugated with both FA-PEG derivatives and alkoxy-PEG derivatives. Such hemoglobin derivative according to the invention exhibit non-toxicity and extended intravascular retention time.

  本发明涉及血红蛋白衍生物，特别是与脂肪酸连接的聚乙二醇（FA-PEG）衍生物和烷氧基聚乙二醇（烷氧基-PEG）衍生物共结合的血红蛋白，以及制备此类血红蛋白衍生物的方法。本发明的各种实施例包括与FA-PEG衍生物和烷氧基-PEG衍生物共结合的交联血红蛋白。根据本发明，这种血红蛋白衍生物表现出非毒性和延长的血管内滞留时间。
• Haemoglobin based blood substitute and method for the preparation thereof
  申请人：Technion Research & Development Foundation Ltd.

  公开号：EP0361719A1

  公开（公告）日：1990-04-04

  Hemoglobin-based blood substitute resulted from stroma-­free hemoglobin, modified with pyridoxal-5′-phosphate and intramolecularly stabilized, followed by polymerization under anaerobic conditions at an extent of above 40%. The new blood substitute is not toxic and possesses the proper oxygen affinity, adequate oncotic pressure and percentage of the undesirable methemoglobin, substant­ially equal to those of whole human blood. Among the main characteristic properties of the novel hemoglobin-based blood substitute the following may be mentioned: appropriate lifetime in circulation upon reconstitution in an appropriate solvent, good oxygen binding and delivery characteristics and appropriate oxygen transport capacity. The method for its preparation is simple and requires common reagents.

  以血红蛋白为基础的血液替代品是由不含基质的血红蛋白经吡哆醛-5′-磷酸修饰和分子内稳定化后，在厌氧条件下聚合而成，聚合度超过 40%。这种新型血液替代品没有毒性，具有适当的氧亲和力、足够的肿瘤压和不受欢迎的高铁血红蛋白的百分比，与全人类血液基本相同。以血红蛋白为基础的新型血液替代品的主要特点如下：在适当的溶剂中重组后，在循环中的寿命适当，具有良好的氧结合和输送特性，以及适当的氧运输能力。其制备方法简单，只需普通试剂。
• Stabilization of functional proteins
  申请人：Modrovich, Ivan E.

  公开号：EP0562624A2

  公开（公告）日：1993-09-29

  Labile analytes are stabilized by reaction with a biostabilizer in the presence of a condensing or linking agent.

  在冷凝剂或连接剂存在的情况下，易变分析物通过与生物稳定剂反应而得到稳定。
• Methods and compositions for optimization of oxygen transport by cell-free systems
  申请人：——

  公开号：US20030083233A1

  公开（公告）日：2003-05-01

  Compositions, and methods of use thereof, for use as blood substitute products comprise aqueous mixtures of oxygen-carrying and non-oxygen carrying plasma expanders and methods for the use thereof. The oxygen-carrying component may consist of any hemoglobin-based oxygen carrier, while the non-oxygen carrying plasma expander my consist of any suitable diluent.

  用作血液替代产品的组合物及其使用方法包括携氧血浆膨胀剂和非携氧血浆膨胀剂的水混合物及其使用方法。载氧成分可由任何基于血红蛋白的载氧剂组成，而非载氧血浆膨胀剂可由任何合适的稀释剂组成。
• EP0143832A4
  申请人：——

  公开号：EP0143832A4

  公开（公告）日：1985-09-02